Related Experiment Video
Updated: Jul 18, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Cytotoxic and Apoptotic Effects of Pinostilbene and Bortezomib Combination Treatment on Human Multiple Myeloma Cells
Anna Staskiewicz1, Erica Wong1, Michael Tucker1
1Department of Pharmaceutical Sciences, College of Pharmacy, Philadelphia College of Osteopathic Medicine-Georgia Campus, Suwanee, GA 30024, USA.
Abstract:
Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow characterized by bone lesions, hypercalcemia, anemia, and renal failure. Bortezomib (BTZ), a common treatment for MM, is a proteasome inhibitor that induces apoptosis in MM cells. However, high doses of BTZ can be very toxic, signifying a need for a synergistic drug combination to improve treatment efficacy. Resveratrol (RES), a phenolic compound found in grapes, has been shown to inhibit MM cell growth. We sought to identify a synergistic combination of BTZ with a RES derivative and analyze the effects on reducing viability and inducing apoptosis in human MM cells. BTZ as well as RES and its derivatives pinostilbene (PIN) and piceatannol (PIC) decreased MM cell viability in a dose- and time-dependent manner and increased expression of cleaved proapoptotic proteins poly(ADP-ribose) polymerase 1 (PARP1) and caspase-3 in a dose-dependent manner. The combination of 5 nM BTZ and 5 μM PIN was identified to have synergistic cytotoxic effects in MM RPMI 8226 cells. MM RPMI 8226 cells treated with this combination for 24 h showed increased cleaved PARP1 and caspase-3 expression and higher percentages of apoptotic cells versus cells treated with the individual compounds alone. The treatment also showed increased apoptosis induction in MM RPMI 8226 cells co-cultured with human bone marrow stromal HS-5 cells in a Transwell model used to mimic the bone marrow microenvironment. Expression of oxidative stress defense proteins (catalase, thioredoxin, and superoxide dismutase) in RPMI 8226 cells were reduced after 24 h treatment, and cytotoxic effects of the treatment were ameliorated by antioxidant N-acetylcysteine (NAC), suggesting the treatment impacts antioxidant levels in RPMI 8226 cells. Our results suggest that this combination of BTZ and PIN decreases MM cell viability synergistically by inducing apoptosis and oxidative stress in MM cells.
Insights
A novel drug combination of bortezomib (BTZ) and pinostilbene (PIN) shows synergistic effects against multiple myeloma (MM) cells. This combination enhances apoptosis and reduces MM cell viability, offering a promising new therapeutic strategy.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Multiple myeloma (MM) is a bone marrow cancer requiring effective treatments.
- Bortezomib (BTZ) is a proteasome inhibitor used for MM, but high doses cause toxicity.
- Resveratrol (RES) and its derivatives show potential in inhibiting MM cell growth.
Purpose of the Study:
- To identify a synergistic combination of BTZ with a RES derivative for MM treatment.
- To analyze the effects of the combination on MM cell viability and apoptosis.
- To investigate the underlying mechanisms, including oxidative stress.
Main Methods:
- Dose- and time-dependent viability assays.
- Western blot analysis for apoptosis markers (cleaved PARP1, caspase-3).
- Transwell co-culture model to mimic the bone marrow microenvironment.
- Assessment of oxidative stress defense proteins and effect of N-acetylcysteine (NAC).
Main Results:
- BTZ, RES, pinostilbene (PIN), and piceatannol (PIC) reduced MM cell viability and increased apoptosis markers.
- A combination of 5 nM BTZ and 5 μM PIN demonstrated synergistic cytotoxic effects.
- The combination significantly increased apoptosis and cleaved PARP1/caspase-3 expression in MM cells.
- Treatment reduced oxidative stress defense proteins, and NAC ameliorated cytotoxic effects.
Conclusions:
- The combination of BTZ and PIN exhibits synergistic cytotoxicity against multiple myeloma cells.
- This synergy is mediated through enhanced apoptosis induction and increased oxidative stress.
- This combination represents a potential therapeutic strategy to improve MM treatment efficacy and reduce toxicity.
Related Concept Videos
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
The Intrinsic Apoptotic Pathway

